Announced
Financials
Sources
Tags
Cross Border
Majority
Private
Denmark
Biotechnology
biotechnology solutions
enzyme technology
Single Bidder
biotechnology solution
Acquisition
Pending
Friendly
Synopsis
Kerry, a taste and nutrition partner for the food, beverage and pharmaceutical markets, agreed to acquire part of the Lactase Enzymes Business of Novozymes and Chr. Hansen for €150m. The Lactase Enzymes Business which includes NOLA® Products, further enhances Kerry's biotechnology solutions capability following the acquisitions of c-LEcta and Enmex. This acquisition adds enzyme technology which helps create lactose-free and sugar reduced dairy products, while preserving their authentic clean taste.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.